Thrombospondin-1 serum levels do not correlate with pelvic pain in patients with ovarian endometriosis

1757-2215-2-18 1757-2215 Brief communication Thrombospondin-1 serum levels do not correlate with pelvic pain in patients with ovarian endometriosis Manero García Manuel mgmanero@unav.es Olartecoechea Begoña bolarteco@unav.es Royo Pedro proyo@alumni.unav.es Alcázar Luis Juan jlalcazar@unav.es

Department of Obstetrics and Gynecology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain

Department of Obstetrics and Gynecology, Hospital San Jorge, Huesca, Spain

Journal of Ovarian Research 1757-2215 2009 2 1 18 http://www.ovarianresearch.com/content/2/1/18 1991711510.1186/1757-2215-2-18 14 8 2009 16 11 2009 16 11 2009 2009 Manero et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objetive

Thrombospondin-1 serum levels is correlate with pelvic pain in patients with ovarian endometriosis.

Patients

Thrombospondin-1 serum levels were prospectively analysed in 51 patients (group A asymptomatic patients or patients presenting mild dysmenorrhea and women comprised group B severe dysmenorrhea and/or chronic pelvic pain and/or dyspareunia) who underwent surgery for cystic ovarian endometriosis to asses whether a correlation exists among thrombospondin-1 serum levels and pelvic pain.

Results

From 56 patients, five cases were ultimateley excluded, because the histological diagnosis was other than cystic ovarian endometriosis (2 teratomas and 3 haemorragic cysts). The mean thrombospondin-1 serum levels in group A was 256,69 pg/ml_+37,07 and in group B was 291,41 pg/ml + 35,59.

Conclusion

Pain symptoms in ovarian endometriosis is not correlated with thrombospondin-1 serum levels.

Introduction

Endometriosis is a common gynaecologic disease of unknown aetiology. The most widely accepted hypothesis for the development of endometriosis is retrograde menstruation. However, some other factor renders certain women susceptible to the implantation and growth of this ectopic endometrium.

Angiogenesis appears as one of the processes involved in the pathogenesis of endometriosis 12. Angiogenic factors are increased in the peritoneal fluid of patients with endometriosis 34 in peritoneal implants 5 and in ovarian endometriomas67.

On the other hand some investigators have found that angiogenesis is related to pelvic pain 8. We speculated that ovarian endometriomas in patients presenting with pelvic pain would have more angiogenesis than those in asymptomatic women and, therefore, their vascular features would be different 9. Previosly, we studied angiogenic factors (VEGF, IL-8) and their relationship with pelvic pain and conclude that these angiogenic factors not correlate with pelvic pain in ovarian endometriosis 10111213.

Angiogenesis is under the control of numerous inducers, including the vascular endothelial growth factor (VEGF) family and inhibitors, such as thrombospondin-1 (TSP-1) 9

The aim of our study was to further investigate thrombospondin-1 serum levels in asymptomatic patients and women with pelvic pain to determine whether this antiangiogenic factor can be used as a serum marker of endometriosis activity.

Patients

Materials and methods

In this prospective study 56 pre-menopausal women (mean age: 34.38 ± 7.07) were enrolled from February 2003 to February 2005. Patients were divided in two groups according to clinical complaints. Group A included asymptomatic patients or patients presenting mild or moderate dysmenorrhea, but without dispareunia or chronic pelvic pain (n = 25) Group B included patients presenting severe dysmenorrhea (with no response to conventional analgesic, treatment such as antiprostaglandins and requiring bed rest) and/or dyspareunia and/or chronic pelvic pain. (n = 26). The degree of pain was established using a visual analogue scale, VAS scale 14.

All patients provided informed consent after the nature of the study was fully explained and Institutional Review Board approval (Clinica Universitaria de Navarra) was obtained before starting the study.

Blood samples were collected from all patients before anaesthesia by venipuncture into 10 cc sterile tubes and were kept at room temperature until centrifugation at 400 × g for 10 minutes. Less than 2 hours were allowed between blood collection and processing. Serum aliquots were then frozen at -80°C until measurement of thrombospondin-1 serum levels.

Serum concentrations of thrombospondin-1 were measured with use of an immunoassay (Quantikine; R&D Systems Inc., Minneapolis, MN). Thrombospondin-1 concentration can be measured in the range of 3.5 to 2,000 pg/mL. Interassay and intra-assay coefficients of variation were <10%.

Statistical analysis

Statistical analysis was performed using the SPSS version 11.0 software (SPSS, Inc., Chicago IL). The mean serum level of thrombospondin-1 was compared in two groups using the Student's t-test for independent samples.

All results of thrombospondin-1 expression were analysed by the Student's t-test. Spearman's correlation coefficient was used to evaluate the relationship between parameters. Statistical significance was set at p < 0,05.

Results

From 56 patients, five cases were ultimateley excluded, because the histological diagnosis was other than cystic ovarian endometriosis (2 teratomas and 3 haemorragic cysts). The presence and type of pelvic adherences, mean rAFS score and stages, and sizes of endometriomas were not statistically different between groups 15.

The mean thrombospondin-1 serum levels in group A was 256,69 pg/ml_+37,07 and in group B was 291,41 pg/ml + 35,59. In order to verify whether this observation could have been biased by the lack of control for several possible confounders, the mean thrombospondin-1 serum levels was adjusted with respect to gravidity, length of menses, infertility and BMI in a univariate general linear model 16. Using this model, no significant difference was observed in mean thrombospondin-1 serum levels between two groups.

Serum thrombospondin-1 concentration did not correlate with the diameter of the endometriomas and the severity of the endometriosis, assessed according to revised AFS scores.

Conclusion

The presence of ovarian cystic endometriosis is associated with pelvic pain in women suffering this disease 8. On the other hand, angiogenic factors have been found increased in ovarian endometriomas 6. Angiogenesis is related to vascularization. Therefore, a correlation between vascularization and the presence of pelvic pain might be assumed. Some studies assessing angiogenic activity in endometriosis have used either morphometric or inmunohistochemical techniques in endometriotic tissue 6171819. Other studies have evaluated vascular activity measuring serum 1620 or peritoneal fluid concentrations of angiogenic factors, such as VEGF 13. Previously, some authors assessed that angiogenic factors are increased in the serum of patients with endometriosis 18 when compared with patients without endometriosis. Recently, Ohata has been demostrated that thrombospondin-1 serum levels were higher in patients with ovarian endometrioma than in patients without endometriosis 2122.

Previously, we demonstrated for the first time that IL-8 and VEGF serum levels is not increased in patients diagnosed of ovarian endometriomas who presenting pelvic pain as compared with those who are asymptomatic. Some authors, have been demonstrated that expresion of TSP-1 is higher in endometriotic lesions and is associated to the extent of their vascularization.

In the present study, we analysed if thrombospondin-1 serum levels were correlated with ovarian endometrisosis and pelvic pain. We conclude that although thrombospondin-1 seems to play a key role in the local development of endometriotic lesions, the disease is not associated with a significant modulation in the levels of circulating thrombospondin-1 and the activity of endometriosis can not be monitored using serum levels.

Although recently studies have demonstrated that IL-8 and thrombospondin-1 serum level improve diagnostic reability of ovarian endometriosis we believe that the optimal serum marker should be used to monitoring the response of new antiangiogenic agents used in endometriosis treatment.

Abbreviations

pg/ml: picograms/mililiter; VEGF: Vascular Endothelium Growth Factor; IL-8: Interleukin 8; TSP-1: Thrombospondin-1; VAS: Visual Analogic Scale; °C: Centrigrade degrees; BMI: Body Mass Index; rAFS scores and stages: revised American Fertility Society scores and stages.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MGM, designed the study and wrote the paper. BO and PR reviewed the literature related and corrected all areas in the text including english language of the paper, covering this fields. JLA was responsible for the methodological and statistics corrections.

Vascular endothelial growth factor (VEGF) in endometriosis Donnez J Hum Reprod 1998 13 1686 1690 10.1093/humrep/13.6.1686 9688413 Angiogenesis in endometriosis Matsuzaki S Canis Darcha C Gynecol Obstet Invest 1998 46 111 115 10.1159/000010013 9701691 Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis McLaren J Hum Reprod 1996 11 220 223 8671190 Angiogenic factors in endometriosis Taylor RN Lebovic DI Mueller MD Ann N Y Acad Sci 2002 955 89 100 10.1111/j.1749-6632.2002.tb02769.x 11949968 Immunohistochemical localization of acidic and basic fibroblast growth factors in normal human endometrium and endometriosis and the detection of their mRNA by polymerase chain reaction Ferriani RA Charnock-Jones DS Prentice A Thomas EJ Smith SK Hum Reprod 1993 8 11 6 7681435 Expression of platelet-derived endothelial cell growth factor (PD_ECGF) related to angiogenesis in ovarian endometriomata Fujimoto J Sakaguchi H Hirose R J Clin Endocrinol Metab 1999 84 359 362 10.1210/jc.84.1.359 9920107 Immunohistochemical analysis of vascular endothelial growth factor cellular expression in ovarian endometriomata Goteri G Fertil Steril 2004 81 1528 1533 10.1016/j.fertnstert.2003.11.035 15193472 Endometriosis: what a pain it is Vercellini P Semin Reprod Endocrinol 1997 15 251 261 10.1055/s-2008-1068755 9383834 Transvaginal colour Doppler in patients with ovarian endometriomas and pelvic pain Alcázar JL Hum Reprod 2001 16 2672 2675 10.1093/humrep/16.12.2672 11726594 Interleukin-8 serum levels do not correlate with pelvic pain in patients with ovarian endometriomas Manero MG Alcazar JL Fertil Steril 2009 Article 19423093 Interleukin-8 as a macrophage-derived mediator of angiogenesis Koch AE Polverini PJ Kunkel SL Harlow LA DiPietro LA Elner VM Elner SG Strieter RM Science 1992 11; 258 1798 1801 10.1126/science.1281554 Pathogenetic significance of increased levels of interleukin-8 in the peritoneal fluid of patients with endometriosis Iwabe T Harada T Tsudo T Tanikawa M Onohara Y Terakawa N Fertil Steril 1998 69 924 930 10.1016/S0015-0282(98)00049-1 9591504 Vascular endothelial growth factor (VEGF) and ovarian endometriosis: correlation between VEGF serum levels, VEGF cellular expression, and pelvic pain García-Manero M Alcazar JL Toledo G Fertil Steril 2007 88 513 515 10.1016/j.fertnstert.2006.11.117 17296185 High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata Fasciani A D'Ambrogio G Bocci G Monti M Genazzi AR Artini PG Mol Hum Reprod 2000 6 50 54 10.1093/molehr/6.1.50 10611260 The validation of visual analogue scales as ratio scale measures for chronic and experimental pain Price DD McGrath PA Rafii A Buckingham B Pain 1983 17 45 56 10.1016/0304-3959(83)90126-4 6226917 Revised American Fertility Society classification of endometriosis Sterility AF Fertil Steril 1985 43 351 352 3979573 Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis Gagne D Hum Reprod 2003 18 1674 1680 10.1093/humrep/deg326 12871881 Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities Nisolle M Donnez J Fertil Steril 1997 68 585 596 10.1016/S0015-0282(97)00191-X 9341595 Angiogenesis: a new theory for endometriosis Healy DL Hum Reprod Update 1998 4 736 740 10.1093/humupd/4.5.736 10027628 Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines Matalliotakis IM Int Immunopharmacol 2003 3 81 89 10.1016/S1567-5769(02)00216-3 12538037 The follicular and endocrine environment in women with endometriosis: local and systemic cytokine production Pellicer A Fertil Steril 1998 70 425 431 10.1016/S0015-0282(98)00204-0 9757870 Serum interleukin-8 levels are elevated in patients with ovarian endometrioma Ohata Y Harada T Miyakoda H Taniguchi F Iwabe T Terakawa N Fertil Steril 2008 90 994 999 10.1016/j.fertnstert.2007.07.1355 18635170